Evaluation of E1b gene-attenuated replicating adenoviruses for cancer gene therapy by 源�二쇳빆 et al.
Evaluation of E1B gene-attenuated replicating adenoviruses
for cancer gene therapy
Jaesung Kim,1 Jae Yong Cho,2 Joo-Hang Kim,1 Kyeong Cheon Jung,3 and Chae-Ok Yun1
1Institute of Cancer Research, Yonsei Cancer Center and 2Department of Internal Medicine, Yonsei University
College of Medicine, Seoul, South Korea; and 3Department of Pathology, Hallym University College of Medicine,
Chunchon-Si, Kangwon-Do, South Korea.
Gene-attenuated replication-competent adenoviruses are emerging as a promising new modality for the treatment of cancer. For the
aim of improving adenoviral vectors for cancer gene therapy, we have constructed genetically attenuated adenoviral vectors with
different combinations of E1B genes and investigated the possibility of enhanced oncolytic and replication effects of these engineered
replication-competent adenoviruses. We show here that the cytolytic potency of each gene-attenuated replicating adenovirus
differed significantly depending on the presence or deletion of E1B 55 kDa and E1B 19 kDa function. More specifically, among the
constructed vectors (Ad-E1B19, Ad-E1B55, Ad-E1B19/55, and Ad-wt), E1B 19 kDa–inactivated adenovirus (Ad-E1B19)
was the most potent against all tumor cells tested, inducing the largest - sized plaques and marked CPE. Further, cells infected with
either Ad-E1B19 or E1B19/55 kDa–deleted adenovirus (Ad-E1B19/55) showed complete cell lysis with disintegrated cellular
structure, whereas cells infected with Ad-wt maintained intact cellular and nuclear membrane with properly structured organelles.
TUNEL and DNA fragmentation assay also revealed that the Ad-E1B19 or Ad-E1B19/55 adenovirus- infected cells showed more
profound induction of apoptosis in comparison to wild- type adenovirus- infected cells. The presence of E1B 55 kDa gene was
required for efficient viral replication and deletion of E1B 19 kDa function in replicating adenovirus- induced apoptosis, leading to
increased cytopathic effects. Moreover, Ad-E1B19 adenovirus showed a better antitumor effect than other E1B -attenuated
adenoviruses. Taken together, the replicating adenoviruses deleted in E1B 19 kDa function may serve as an improved vector for
anticancer gene therapy in combination with apoptosis - inducing modalities such as chemotherapeutic agents and radiation therapy.
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Selective replication of viral agents in tumors may lead toimproved efficacy over nonreplicating agents due to the
self -perpetuating nature of viral multiplication, lysis of the
infected cancer cell, and secondary infections to adjacent
cells. Genetically attenuated adenoviruses are being devel-
oped as selectively replicating antitumoral agents, and
currently, a number of clinical trials with such viruses are
ongoing to treat a variety of cancers.1–3 Initial assessment of
these trials demonstrates that gene-attenuated adenoviruses
have some efficacy and exhibit safety and feasibility of
treatment.2,4 However, studies have also shown that
adenovirus E1B 55 kDa gene deletion conferring selectivity,
i.e., deletion of E1B 55 kDa could endow selective re-
plication, frequently results in reduced potency of the virus
in tumors.5,6 To achieve sufficient antitumor efficacy, gene-
attenuated replicating adenoviruses are currently being
delivered by multiple injections of high- titer virus,6 or in
combination with chemotherapy.7,8 Therefore, the develop-
ment of a novel replication-selective agent with improved
potency would be timely and could be applied more widely
in anticancer gene therapy.
The E1B region encodes for two major proteins, E1B
19 kDa and E1B 55 kDa. E1B 19 kDa protein is a potent
apoptosis inhibitor and a homologue of Bcl-2–related
apoptosis inhibitors.9–12 The antiapoptotic effect of Ad
E1B 19 kDa was initially described by Rao et al,13 who
observed that E1B 19 kDa inhibited adenovirus E1A
protein- induced apoptosis. In several human tumor cell
lines, Ad5 E1B 19 kDa was shown to inhibit p53-induced
apoptosis.14,15 In addition, the antiapoptotic effect of E1B 19
kDa has been demonstrated to be functionally equivalent to
that of Bcl-2 in terms of its ability to inhibit apoptosis
induced by growth factor deprivation, treatment with gamma
radiation, glucocorticoid, and various cytotoxic drugs.16
Recently, combination studies with cisplatin or paclitaxel
with adenovirus-mediated proapoptotic Bax gene induction
have shown a synergistic increase of cytotoxicity against
cancer cells.17,18 However, adenoviral vectors used in these
studies contained intact E1B 19 kDa that can interfere with
the antitumor effect by blocking the apoptotic pathway
induced by a variety of chemotherapeutic agents. Therefore,
the development of E1B 19 kDa gene-attenuated adenovirus
could greatly enhance cellular cytotoxicity caused by
replicating adenovirus and subsequently could be used
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alone, or in combination with cytotoxic agents inducing
apoptosis -mediated cell death.
Besides interfering with the p53 function during viral
infection, E1B 55 kDa protein also performs other functions
that are important in viral replication. During the early phase
of infection, E1B 55 kDa counteracts E1A functions that
would otherwise lead to the stabilization of p53 and the in-
duction of apoptosis.14 In the late phase, E1B 55 kDa, acting
together with the E4-orf6 gene product, is required for ef-
ficient cytoplasmic accumulation and translation of adeno-
viral mRNA.19–21 This is accompanied by shutting off of
host mRNA nuclear export and host protein synthesis. Gene-
attenuated replicating adenovirus, ONYX-015 (originally
named dl1520), has a deletion in the E1B transcription unit
that removes the gene for E1B 55 kDa. This agent has been
tested in phases I and II clinical trials for head and neck cancer,
pancreatic carcinoma, ovarian cancer, colorectal carcinoma,
non small cell lung carcinoma, and oral dysplasias.2,3 Despite
clear evidence of antitumoral activity in some patients,
treatment with ONYX-015 as a single agent has not produced
classically defined tumor responses. Thus, although targeting
the p53 pathway produces specific cytotoxicity against the
p53 mutated cancer cells, the imperfection of the vector sys-
tem may limit the therapeutic value in in vitro and in in vivo.
Previously, we have shown that the E1B 55 kDa–deleted
recombinant adenovirus vector (YKL-1) exhibited the
tumor-selective replication, but showed reduced cytopathic
effect (CPE) in several tumor cell lines.22 The reduced
potency of dl1520 or YKL-1 may be due to a loss of an
important function of E1B 55 kDa that is involved in efficient
viral replication such as viral mRNA nuclear transport and
accumulation in the cytosol.
Recently, the E1B 19 kDa–deleted adenovirus has been
developed, showing increased induction of apoptosis and
opening the possibility of enhancing potency of genetically
attenuated replicating adenoviruses that can be ultimately
used in a clinical setting.23 In that context, it would be highly
desirable to potentiate the cell killing of replicating
adenoviruses by enhancing the viral -mediated cell lysis as
well as the oncolytic effects of efficient viral replication.
Based on these considerations, attempts to engineer E1B 19
kDa and E1B 55 kDa genes have been sought to advance the
therapeutic value of replicating adenovirus for cancer gene
therapy. However, to date, a systematic comparison and
assessment of the therapeutic values of adenoviral E1B 19
kDa and 55 kDa gene-modified adenoviral vectors have not
been accomplished. In this study, we have constructed
genetically attenuated adenoviral vectors with different
combinations of E1B genes and have investigated the
possibility of enhanced oncolytic and replication effects of
these genetically engineered replicating adenoviruses.
Materials and methods
Cell lines and cell culture
All cell lines, with the exception of Hep3B, were cultured in
DMEM supplemented with 10% fetal bovine serum and
penicillin–streptomycin (100 IU/mL). The Hep3B cell line
was maintained in modified Eagle’s medium supplemented
with 10% fetal bovine serum and penicillin–streptomycin
(100 IU/mL). HEK293 (human embryonic kidney cell line
expressing the adenoviral E1 region), liver cancer cell line
(Hep3B), lung cancer cell lines (A549 and H460), cervical
cancer cell line (C33A), and brain cancer cell line (U343)
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA).
Construction of gene-attenuated adenoviruses
To generate the E1B19/55 kDa–deleted recombinant adeno-
virus (Ad-E1B19/55), the E1A region from nucleotide
343–1657 bp was amplified by polymerase chain reaction
(PCR) with the following primer set: 50 -TTATTGGA-
TCCTTTGTCTAGGGCCGCGGG-30 as the sense primer
and 50 -CCAGGATCCAGATCTCCCCATTTAACACGCC-
ATGC-30 as the antisense primer. The adenoviral shuttle
vector, pXC1 (Microbix, Ontario, Canada), containing the
E1 region of adenovirus type 5, was used as a template. The
PCR product containing E1A with BamHI site (underlined)
at both 50 and 30 ends and BglII (underlined) at the 30 end was
digested with BamHI and then subcloned into the BglII site
of pCA14 (Microbix), generating a pCA14-E1A shuttle
vector. The nucleotide sequence of the amplified PCR
product was verified using an ABI PRISM377 automatic
DNA sequencer. The pCA14-E1A shuttle vector was
linearized by XmnI digestion. The adenovirus vector
vmdl324Bst (obtained from Dr Verca at the University of
Fribourgh, Switzerland) containing the Ad5 genome deleted
in the E1 region (281–4640 in nucleotide of Ad5) and the
E3 region (28596–30470 in nucleotide of Ad5) was
linearized with BstBI digestion. The linearized pCA14-
E1A was cotransformed into Escherichia coli BJ5183
together with the BstBI-digested vmdl324Bst for homolo-
gous recombination.47 To verify the respective homologous
recombinants, the plasmid DNA purified from overnight
E. coli culture was digested with HindIII, and the digestion
pattern was analyzed. The proper homologous recombinant
adenoviral plasmid DNA was digested with PacI and
transfected into 293 cells to generate the E1B -deleted
adenovirus, Ad-E1B19/55.
To construct the E1B19 kDa–inactivated adenovirus (Ad-
E1B19), pXC1 was digested with XbaI and KpnI, and sub-
sequently subcloned into the XbaI and KpnI sites of pSP72
cloning vector, generating pSP72/E1B19. Then, the site -
directed mutagenesis (Stratagene, La Jolla, CA) in pSP72/
E1B19 was accomplished by PCR amplification using
50 -GTTACATCTGACCTCCTGTAGGCTAGCGAGTGTT-
TGGAAG-30 as the sense primer and 50 -CTTCCAAA-
CACTCGCTAGCCTACAGGAGGTCAGATGTAAC-30 as
the antisense primer. The primers were designed to create a
stop codon (bold, italicized) and a new NheI site (under-
lined) in the region of start codon of E1B 19 kDa. The new
NheI site was introduced to confirm the mutation of PCR
product. The mutated region was verified using an automatic
sequencer. The resulting mutated plasmid pSP72/E1B19
was digested with XbaI and KpnI, and subcloned into the
XbaI and KpnI sites of pXC1. Then, homologous recom-
bination was induced in E. coli BJ5183 with vmdl324Bst
as described above. Replication- incompetent adenovirus
(Ad-E1), E1B 55 kDa–deleted adenovirus (Ad-E1B55;
YKL-1), and wild- type recombinant adenovirus (Ad-wt)
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were also prepared.22 All viruses were propagated in
HEK293 cells and purified according to standard methods.22
Viruses used in this study are shown in Figure 1, and
Ad-E1 and Ad-wt were used as controls for E1B gene-
attenuated adenoviruses.
PCR analysis of E1B mutant adenoviruses
U343 cells were infected with Ad-E1, Ad-E1B19/55,
Ad-E1B19, Ad-E1B55, or Ad-wt at a multiplicity of
infection (MOI) of 10. After 2 days postinfection, viral DNA
was isolated with a genomic isolation kit (Qiagen, Santa
Clarita, CA). PCR was accomplished using three kinds of E1
region–specific primer sets corresponding to E1A, E1B 19,
and E1B 55 kDa, and the expected sizes of PCR products
were 479, 429, and 338 bp, respectively. PCR product
fragments were then resolved on a 1.8% agarose gel and
visualized by UV fluorescence.
Western blot analysis of Ad E1A and E1B 19 kDa protein
expression
Cells were lysed in 50 mM Tris–HCl (pH 7.6), 1% Nonidet
P-40 (NP-40), 150 mM NaCl, and 0.1 mM zinc acetate in
the presence of a protease inhibitors. Protein concentration
was determined using the Lowry method (Bio-Rad,
Hercules, CA). Ten micrograms of each sample was
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). The gels were then electro-
blotted onto a nitrocellulose membrane. Membranes were
blocked in TBST (50 mM Tris–HCl, pH 7.6, 150 mMNaCl,
0.2% Tween 20) containing 5% dry milk overnight at 48C.
After blocking, membranes were incubated with a rabbit
polyclonal IgG against E1A, a mouse monoclonal IgG
against E1B 19 kDa, or a mouse monoclonal IgG against
E1B 55 kDa (a generous gift from Dr Thomas Dobner in
University of Regensburg, Germany). The secondary anti-
bodies were goat anti–rabbit IgG horseradish peroxidase
(HRP) or goat anti–mouse IgG HRP. Finally, the blots
were developed using enhanced chemiluminescence (ECL)
(Amersham Pharmacia, Arlington Heights, IL).
CPE assays
To evaluate the CPE, 2–8104 cells were plated onto a
24-well plate at about 30–80% confluence, and then
infected with Ad-E1, Ad-E1B19/55, Ad-E1B19,
Ad-E1B55, or Ad-wt at an MOI of 0.1–10. Their killing
effect was monitored daily under a microscope. At the mo-
ment that cells infected with any one of the virus at an MOI
of 0.1 exhibited complete cell lysis, cells on the plate were
then stained with 0.5% crystal violet in 50% methanol.
For viral replication assays, cells were grown as described
for the CPE assays but were subsequently infected at an MOI
of 1 with either E1B mutant or control adenovirus (Ad-E1
or Ad-wt). Forty-eight hours postinfection, both cells and
supernatant were collected for virus titration analysis. Cell
lysates underwent three cycles of freezing and thawing, and
serial dilutions of supernatants and lysates were tittered on
293 cells.
Electron microscope (EM) cytology
A549 cells were infected with Ad-E1B19 or Ad-wt at
an MOI of 10. Four days postinfection, cells were gently
trypsinized and pelleted for 5 minutes at 3000 rpm in a
microcentrifuge tube. After washing with phosphate-
buffered saline (PBS), pellets were fixed for 4 hours at
48C in 2.5% glutaraldehyde in 0.1 M sodium cacodylate
buffer (pH 7.3) containing 2% sucrose and 1 mM calcium
chloride. They were then postfixed with 1% OsO4 in 0.1 M
cacodylate–HCl, pH 7.4, for 1 hour. The samples were
dehydrated in a gradient series of ethanol, embedded in
Epon812, and examined using an EM.
Virus production assay
To assay for viral growth, cells were plated onto a six-well
plate at about 70% confluence, and then infected with Ad-
E1, Ad-E1B19/55, Ad-E1B19, Ad-E1B55, or
Ad-wt at an MOI of 1. At various times of incubation at
378C, supernatant and cells were collected and freeze-
thawed three times to release the viruses. Supernatant and
monolayer samples were assayed by plaque assay to
determine the virus titer.
Plaque development assay
Plaque development assay was carried out on 293, Hep3B,
and U343 cell lines as described previously.48 Briefly,
monolayers of each cell line were infected with serial diluted
adenoviruses in six-well plates. After 2 hours of incubation
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Figure 1 Schematic representation of three E1B mutant adenovi-
ruses, Ad-E1B19, Ad-E1B55, and Ad-E1B19/55, along with
Ad-E1 and Ad-wt. Ad-E1 has the whole E1 region deleted; Ad-
E1B19 contains the normal E1A and E1B55 kDa, but is E1B19 kDa
translation initiation codon–mutated; Ad-E1B55 contains the nor-
mal E1A and E1B19 kDa, but is E1B55 kDa-deleted; Ad-E1B19/55
contains E1A, but is E1B19 kDa- and E1B55 kDa-deleted.
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at 378C, the infected cells were overlaid with 4 mL of 0.7%
SeaPlaque agarose in DMEM with 5% fetal bovine serum.
Following 7–9 days of incubation, agarose overlay was
removed after soaking with 10% trichloroacetic acid for 30
minutes, and the remaining cells were stained with 0.5%
crystal violet in 50% methanol.
TUNEL assay
Apoptosis was also analyzed by terminal deoxynucleotidyl
transferase (TdT)–mediated dUTP nick end labeling
(TUNEL) assay as described previously.22 Briefly, A549
cells were plated on a chamber slide 1 day prior to infection,
and treated with Ad-E1B19/55, Ad-E1B19, Ad-
E1B55, or Ad-wt at an MOI of 2. After 4 days of infection
or treatment with 1 M camptothecin (CPT), infected cells
were rinsed with PBS. Samples were then processed
according to the instructions in the ApopTag kit (Oncor,
Gaithersburg, MD) for the detection of cleaved deoxyribo-
nucleic acid in situ using the TdT-mediated deoxyuridine 50 -
triphosphate-biotin nick end labeling (TUNEL)method. The
apoptotic cells were counted under magnification (400) in
10 selected fields. More than 2000 cells were counted to
calculate the percentages of TUNEL-positive cells (apop-
totic cell ratio).
DNA fragmentation assay
Confluent cultures were treated with CPTat 1 Mor infected
with Ad-E1, Ad-E1B19, Ad-E1B55, Ad-E1B19/
55, or Ad-wt at an MOI of 10. Cells were harvested and
suspended in a lysis buffer (10 mM Tris–HCl, pH 8.0, 100
mM NaCl, 25 mM EDTA, 0.5% SDS, and 100 g/mL
Proteinase K) for 20 hours at 378C. DNAwas extracted with
a mixture of phenol and chloroform, precipitated by ethanol,
dried, and dissolved in a TE buffer. DNA samples were
analyzed by electrophoresis on a 2% agarose gel containing
ethidium bromide (0.5 g/mL) and then visualized under a
UV illuminator.
Antitumor effect of E1B mutant adenoviruses in vivo
The antitumor effect of the following viruses was tested in
vivo: Ad-E1, Ad-E1B19, Ad-E1B55, Ad-E1B19/
55, and Ad-wt. Five- to 6-week-old female nude mice were
purchased from Charles River (Yokohama, Japan). Tumors
were implanted on the abdomen of each animal by sub-
cutaneous injection of 107 tumor cells in 100 L of PBS.
Tumor growth was monitored on a 2- to 3-day interval by
measuring the length and width of the tumor with a caliper.
Tumor volume was calculated using the following formula:
volume=0.523Lw2. When tumors reached a range of 60–
70 mm3, animals were randomized into five groups of six
animals each. First day of treatment was designated as day 1.
Adenoviruses were administered intratumorally (5108
PFU per tumor in 50 L of PBS) on days 1, 3, and 5.
Tumor growth delay was assessed by taking measurements
on a 2- to 3-day interval. When the tumors reached the
maximum acceptable size, mice were sacrificed and their
tumors were excised and analyzed histologically (hematox-
ylin and eosin). Tumor responses to each treatment were
compared by Mann-Whitney test.
Results
Generation and characterization of E1B mutant
adenoviruses
To characterize and compare the E1B mutant adenoviruses’
potential for cell killing effect, three E1B -attenuated
adenoviruses (Ad-E1B19, Ad-E1B55, and Ad-
E1B19/55) were developed as described in Materials
and Methods. First, Ad-E1B19 was designed to be
deficient of the E1B 19 kDa protein by inserting a stop
codon in the region of E1B 19 kDa translation initiation
codon. Second, Ad-E1B55, as described previously,
lacked the E1B 55 kDa gene.22 Finally, Ad-E1B19/55
was designed to express neither the E1B 19 kDa nor the 55
kDa proteins due to the deletion of both genes. All three
constructs were created in adenovirus subtype 5 dl324
background (Fig 1).
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Figure 2 A: The E1 region–specific primer sets corresponding to
E1A, E1B19 kDa, and E1B55 kDa are shown below the diagram of
E1 region of adenovirus genome, and each expected size of PCR
products is 479, 429, and 338 bp, respectively. B: PCR product
analysis of E1B mutant adenoviruses. Left marker (GIBCO, Gaithers-
burg, MD), 1 -kb DNA ladder. The presence of each PCR product ve-
rified the presence of the gene deletion. C: Detection of the E1A, E1B
19 kDa, and E1B 55 kDa protein by Western blot analysis. Twenty-
four hours after infection, total protein from A549 cells infected with
Ad-E1, Ad-E1B19, Ad-E1B55, Ad-E1B19/55, or Ad-wt at a
dose of 10 MOI was analyzed with anti -E1A, anti -E1B19, or anti -
E1B55 antibody as described in Materials and methods.
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Gene constructs of each generated adenoviruses were
verified by PCR using appropriate primer sets amplifying
each E1 region corresponding to E1A, E1B 19 kDa, and
E1B 55 kDa genes (Fig 2A). The U343 brain tumor cell line
was infected with each E1B mutant adenovirus at an MOI of
10 along with Ad-E1 and Ad-wt as a negative and a
positive control, respectively. After 2 days postinfection,
viral DNA was isolated and subsequently used for PCR
amplification using three E1 -specific primer sets. As
expected with the E1A -specific primer set, PCR generated
the DNA fragment of 489 bp from all samples except Ad-
E1–infected U343 cells (Fig 2B). Deletion of E1B 55 kDa
gene in Ad-E1B55 genome was confirmed by PCR
amplification using E1B 55 kDa–specific primer set,
resulting in no PCR product of 338 bp. However, E1A
(479 bp) and E1B 19 kDa (429 bp) DNA fragments were
amplified with E1A- and E1B 19 kDa–specific primers,
respectively, indicating that Ad-E1B55 had a deletion of
E1B 55 kDa gene but that the E1A and E1B 19 kDa regions
were still intact in the genome. The Ad-E1B19/55
genome structure was verified by PCR amplification,
generating only a E1A -specific PCR product (479 bp) but
not E1B 19 kDa and E1B 55 kDa products. This result
indicated that E1B 19 kDa and E1B 55 kDa genes were
properly deleted in Ad-E1B19/55 genome. When Ad-
E1B19–infected U343 cell–derived genomic DNA was
amplified by three E1 region-specific primer sets, three
products corresponding to E1A, E1B 19 kDa, and E1B 55
kDa were obtained. Ad-E1B19 genome, which only has a
change of an initiation codon at the stop codon but retained
all coding sequences of E1B 19 kDa region, resulted in
amplification of all three PCR-amplified DNA fragments.
To verify the gene composition of the three E1B mutant
adenoviruses, E1A, E1B 19 kDa, and E1B 55 kDa protein
expressions were evaluated by immunoblotting with anti -
E1A, anti–E1B 19 kDa, anti–E1B 55 kDa antibodies. As
shown in Figure 2C, no expression of E1B 19 kDa was
found in cell lysates derived from cells infected with Ad-
E1B19 or Ad-E1B19/55 adenoviruses in contrast to
those infected with Ad-E1B55 or Ad-wt adenoviruses.
The expression of E1B 55 kDa was detected in cells infected
with Ad-E1B19 or Ad-wt in contrast to those infected
with Ad-E1B55 or Ad-E1B19/55. Next, as expected,
E1A protein was well expressed in cells infected with each
E1B -attenuated adenovirus or wild- type adenovirus but not
with Ad-E1 adenovirus. These results confirmed that, as
intended, all three E1B mutant adenoviruses possessed
proper E1B gene organization and expression pattern.
Evaluation of cell killing effect of E1B mutant adenoviruses
To quantitatively assess adenovirus replication–dependent
cell killing effects, cell cytotoxicity of each mutant
adenovirus was analyzed by an in vitro CPE assay. Cells
were grown to 50–80% confluence and then infected at an
MOI of 0.1–10. For control, cells were infected in parallel
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Figure 3 CPE effects of replicating adenoviruses in vitro. Monolayer
of cells was infected with different viruses, as indicated. Replication-
incompetent adenovirus Ad-E1 and wild - type adenovirus Ad-wt
served as controls. When cells infected with any one of adenoviruses
at an MOI of 0.1 were completely lysed, cells remaining on the plates
were fixed and stained with crystal violet.
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Figure 4 Morphology of U343 cells infected with Ad-E1 (A), Ad-
E1B19/55 (B), Ad-E1B19 (C), Ad-E1B55 (D) or Ad-wt (E).
Infections were performed at an MOI of 10 as described in Materials
and methods. Micrographs of infected cells were taken at 4 days
postinfection.
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with nonreplicating adenovirus Ad-E1 and wild- type
adenovirus. As shown in Figure 3, Ad-E1B19 exerted
marked CPE against all tumor cell lines tested. The cell lysis
capacity of Ad-E1B19 was about 10–100 times greater
than either Ad-E1B55 or Ad-E1B19/55, and about 5–
20 times greater than wild adenovirus Ad-wt. At similar
MOIs, the decrease in viable cells was significantly more
evident in cells infected with Ad-E1B19 than in those with
any other E1B mutant adenoviruses. These results demon-
strated that the loss of E1B 19 kDa enhanced adenoviral lytic
potency over that of other E1B mutant adenoviruses as well
as that of wild type. In regards to comparison of Ad-
E1B19/55 to Ad-E1B55 adenovirus, Ad-E1B19/55
adenovirus exerted higher potency of cell killing over Ad-
E1B55 adenovirus. More specifically, Ad-E1B19/55
showed about 20 times greater cytotoxicity than Ad-
E1B55 adenovirus in A549 cells, and about 2–5 times
greater potency in C33A, H460, Hep3B, U251N, and U343
cells. Overall, these four replication-competent adenovi-
ruses exerted varied CPE in the order of Ad-E1B19>Ad-
wt>Ad-E1B19/55>Ad-E1B55.
Different rates of cell death were also observed morpho-
logically. U343 cells infected with Ad-E1, Ad-E1B19,
Ad-E1B55, Ad-E1B19/55, or Ad-wt adenovirus at an
MOI of 10 were observed by light microscope up to 7 days.
Ad-E1 adenovirus–infected cells showed no CPE during
the observed time course. Cells infected with Ad-E1B19
exhibited obvious CPE and cell lysis by 2 days postinfection,
whereas cells infected with other Ad E1B mutants or with
Ad-wt were nearly all intact until 3 days postinfection, and
cell death progressed from days 4 to 7. A representative
example of these cells at 4 days postinfection is shown in
Figure 4. Cell death process by infection with Ad-E1B19
was faster than that of any other adenoviruses.
It has been noted that cells infected with E1B 19 kDa–
attenuated adenoviruses, Ad-E1B19 andAd-E1B19/55,
showed distinct morphology in the CPE in that the cell
membrane was almost completely lysed and cellular structure
was severely disintegrated (Fig 4). In comparison, cells
infected with Ad-E1B55 or Ad-wt showed typical
adenovirus -mediated cell lysis, having cells rounded up and
detached from the plastic dishes into floating cells and
forming grape- like clusters. The floating cells were highly
light- refractive and majority of these cells were viable as
judged by viability studies using trypan blue exclusion assay.
The morphological difference observed was further
examined by EM. At 4 days postinfection at an MOI of
10, majority of A549 cells infected with Ad-E1B19
adenovirus were lysed, whereas nearly all Ad-wt–infected
cells were intact. The nuclei in the Ad-wt–infected cells
were extremely swollen, occupying nearly the entire cell
(Fig 5A). Nuclei were packed with viruses but the nuclear
membrane still appeared to be intact. In some cells, crystals
of viruses were observed (Fig 5D). All intracellular
organelles in Ad-wt–infected cells were intact and retained
proper structure. However, cells infected with Ad-E1B19
were completely lysed. The cellular membrane and nuclear
membranes were severely disintegrated and not distinct
(Fig 5B). The intracellular organelles were also hardly
distinguished, and some showed ballooning degeneration.
Viral particles were observed to spread out in the cytoplasm.
Figure 5 Electron micrographs of uninfected Ad-wt (A,D) or Ad-
E1B19 (B,E) and uninfected (C,F) A549 cells at 4 days post-
infection. Cells were infected at an MOI of 10 as described in Materials
and methods. Typical morphologies are shown. Representative low
power (4,400) (A–C) and high power ( 12,000) (D–F) images
are shown.
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Figure 6 Virus production assay. Monolayers of 293 and U343 cells
were infected with Ad-E1, Ad-E1B19/55, Ad-E1B19, Ad-
E155, or Ad-wt at an MOI of 1. The virus present in cell and
supernatant was extracted at the indicated days postinfection, and
titers were determined by plaque assay.
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These ultramicroscopic features favor necrosis rather than
apoptosis in that the cells do not exhibit the typical features
of apoptosis, i.e., cell shrinkage, membrane blebbing, and
membrane-bound apoptotic bodies. However, one of major
characteristics of apoptosis, chromosome condensation,
was observed in Ad-E1B19 adenovirus–infected cells
(Fig 5E). Therefore, it appears that theAd-E1B19 infection
seems to have the capability of inducing both apoptosis as
well as cellular necrosis in the same cells. Recent reports on
murine polyomavirus infection showed specifically that the
infected cells do undergo both apoptosis and necrosis, with
cellular necrosis being the predominant event. Other viruses
such as Newcastle disease virus,24 human herpesvirus 7,25
and infectious pancreatic necrosis virus26 have also been
shown to induce both apoptosis and necrosis in the same cell.
Ad-E1B19 replicates as efficiently as wild- type
adenovirus
Premature cell lysis by induction of apoptosis may lead to
early viral release, possibly resulting in reduction of total
production of viral progeny. Such a loss of viral production
may reduce the efficacy of virotherapy for cancer treatment.
Therefore, the effect of deletion of E1B 19 kDa or presence
of E1B 55 kDa on viral production was examined. To
examine and compare viral replication of each E1B mutant
versus wild- type adenovirus, cells were infected with a
specific adenovirus at an MOI of 1. Then the accumulation
of viral particles in culture medium and cell fraction was
determined by a plaque assay. As shown in Figure 6, total
viral yields of Ad-E1B19 and Ad-wt were similar in U343
cells, reaching a plateau after 5 days postinfection (Fig 6A).
Ad-E1B55 and Ad-E1B19/55 virus yields did not
reach a plateau until 8 days postinfection, and the total yield
of virus was less than those of Ad-E1B19 and Ad-wt.
These results indicate that E1B 55 kDa–containing adeno-
viruses, Ad-E1B19 and Ad-wt, replicate very actively,
whereas E1B 55 kDa–deleted adenoviruses, Ad-E1B55
and Ad-E1B19/55, replicate less efficiently in the panel of
cancer cells tested. However, the loss of E1B 19 kDa
function did not affect viral replication. Therefore, the
efficient replication of adenovirus depends on the presence
of E1B 55 kDa, but not on the E1B 19 kDa gene.
Ad-E1B 19 adenovirus induced biggest plaques
Replication and viral spread from cell to cell was visualized
in a plaque development assay. Monolayers of 293, Hep3B,
and U343 cell lines were infected with five different ade-
noviruses, and plaque formation was monitored. Figure 7
shows a representative plaque assay with Ad-E1, Ad-
E1B19, and Ad-wt. The size of plaques formed by Ad-
E1B19 was larger than that of Ad-wt, and more numbers
of plaques were observed in Hep3B and U343 cells.
However, all three adenoviruses (Ad-E1, Ad-E1B19,
and Ad-wt) developed the same number and size of plaques
in the 293 cells, which complement the E1 gene in trans. The
number of plaques formed in the Hep3B cells infected with
E1B mutant adenoviruses was counted at 3, 5, and 8 days
293
Hep3B
Ad- E1B19 Ad-wtAd-∆ E1
U343
∆ 
Figure 7 Plaque morphology of Ad-E1, Ad-E1B19, and Ad-wt
on 293, Hep3B, and U343 cells. After a 2-hour adsorption period,
plates were overlaid with agarose and incubated. At 7–9 days
postinfection, the agarose overlay was removed, stained with crystal
violet, then photographed. Ad-E1B19 lacking E1B 19 kDa mutant
adenovirus developed larger and more number of plaques than Ad-
wt. Nonreplicating adenovirus Ad-E1 did not develop any plaque
except on E1 complementing cell line 293.
Figure 8 Plaque development assay for E1B -attenuated adenovi-
ruses. Hep3B cells were infected with Ad-E1, Ad-E1B19/55,
Ad-E1B19, Ad-E155, or Ad-wt. After 2 hours of adsorption
period, plates were overlaid with agarose and incubated. After 3, 5,
and 8 days postinfection, the agarose overlay was removed. The cells
were then stained with crystal violet and counted. The plaques of Ad-
E1B19 and Ad-wt developed much faster than other E1B mutant
adenoviruses, Ad-E1B19/55 and Ad-E155, but the final titers
obtained for all virus stocks were similar.
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after infection, and plotted in Figure 8. Consistent with
results in Figure 7, Ad-E1B19 showed enhanced plaque
development when compared to other E1B mutants or wild-
type adenovirus. With Ad-E1B19, 92 plaques were
observed at 8 days postinfection vs 78, 25, and 17 plaques
for Ad-wt, Ad-E1B55, and Ad-E1B19/55, respec-
tively (Fig 8B). Therefore, the rate of plaque development
by infection with Ad-E1B19 was faster than any other
E1B mutant adenoviruses tested in this study, including the
wild- type adenovirus. However, the other E1B 19 kDa–
attenuated adenovirus, Ad-E1B19/55, developed plaques
slowly and formed less number of plaques than Ad-wt,
similar to Ad-E1B55 (Fig 8B). Thus, Ad-E1B19/55
and Ad-E1B55 were not as effective as Ad-E1B19 in
promoting cell lysis, not only in CPE assay but also in the
plaque development assay.
Cellular apoptosis is enhanced in the E1B 19
kDa–attenuated adenovirus- infected cells
To examine whether the attenuation of E1B 19 kDa function
could affect the cell death pathway, DNA integrity was
monitored after viral infection. TUNEL and DNA fragmen-
tation assays were used to evaluate the induction of apoptosis
and tumor cell killing. A549 cells, infected with Ad-E1,
Ad-E1B19, Ad-E1B55, Ad-E1B19/55, or Ad-wt at
an MOI of 2, were evaluated for induction of apoptosis by
TUNEL assay after 4 days postinfection. CPT (1 M) was
used as a positive control to induce apoptosis. Infection with
Ad-E1B19 induced the most potent apoptosis, showing
that approximately 46.7% of the nuclei had a nicked DNA,
whereas apoptosis induced by Ad-wt was nearly undetect-
able (4.3%) (Fig 9). The mean percentage of apoptotic cells
induced by each adenovirus is summarized in Table 1. Ad-
E1B19/55 induced apoptosis in about 20% of the infected
cells, whereas Ad-E1B55 induced apoptosis at a very low
rate (6.0%). Thus, DNA is degraded much faster in cells
infected with Ad-E1B19 or Ad-E1B19/55 than in those
infected with Ad-wt or Ad-E1B55. These DNA breaks
have been studied in more detail. The formation of DNA
fragments consisting of multimers of approximately 180 bp
has been regarded as a hallmark of apoptosis.27 Figure 10
shows that E1B 19 kDa–attenuated adenoviruses induced
DNA ladder formation in U343 cells. DNA smear and the
characteristic ladder were observed in cells treated with E1B
19 kDa–attenuated adenoviruses ( lanes 5 and 6) or CPT
(lane 3), but not in the cells treated with Ad-E1 (lane 4),
Ad-E1B55 (lane 7), or Ad-wt ( lane 8). These results
indicate that E1B 19 kDa functions as an antiapoptotic
molecule; thus, the elimination of E1B 19 kDa protein
induced apoptosis and accelerated cell death by adenoviral
infection.
Suppression of growth of established tumors by the E1B
mutant adenoviruses
We subsequently assessed the relative antitumor efficacy of
E1B mutant adenoviruses in a human xenograft model
(human hepatoma cell line, Hep3B, implanted in nude mice).
When the subcutaneously implanted tumors reached 5 mm in
diameter, tumors were injected intratumorally with Ad-E1,
Ad-E1B19, Ad-E1B55, Ad-E1B19/55, or Ad-wt at a
dose of 5108 PFU per animal every 2 days for a total of three
times. In tumors derived from the Hep3B cells, treatment with
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Figure 9 TUNEL staining in A549 cells. At 4 days after treatment
without (A) or with 1 M of CPT (B), or infection with Ad-E1B19/
55 (C), Ad-E1B19 (D), Ad-E1B55 (E) or Ad-wt (F) at an MOI
of 2, apoptotic cells were detected by labeling with DAB (3,30 -
diaminobenzidine ) using terminal deoxynucleotidyl transferase
(counterstained with methyl green). Brown staining indicates positive
staining for DNA strand breakage. Arrows indicate positive staining.
Representative fields of two independent experiments are shown.
Original magnification: 100 and 400.
Table 1 The mean percentage of apoptotic cells induced by each Ads
Untreated CPT (1 mM) Ad–E1B19/55 Ad–E1B19 Ad–E1B55 Ad-wt
Apoptotic cell
ratio (%)
< 1.0 25.8 20.0 46.7 6.0 4.3
A549 cells were infected with Ad-E1B19, Ad-E1B55, Ad-E1B19/55, or Ad-wt at an MOI of 10. Cells were harvested on day 4 after
infection. The TUNEL assay was performed as described in Materials and methods. The number of brown stained cells per 100 cells was
counted. Each of the indicated values reflects the mean of three independent experiments, and is expressed as the percentage of apoptotic cells.
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the replicating adenoviruses significantly suppressed tumor
growth when compared with control adenovirus, Ad-E1.
Control tumors grew very rapidly, with a greater than 33-fold
increase in size by day 31 (day 1, 77.5±39 mm3; day 31,
2541±592 mm3), whereas E1B-attenuated adenoviruses
significantly suppressed the growth of Hep3B tumors (Ad-
E1B19, %T /C=2; Ad-E1B55, %T /C=21; Ad-
E1B19/55, %T /C=8, P<.05) (Fig 11). By day 10,
Ad-E1B19–treated tumors showed a %T /C of 11
(negative number signifies partial regression), with total
tumor regression in one of the six mice tested. Ad-E1B55–
andAd-E1B19/55–treated tumors showed%T /C of 5
and 6, respectively, at this time period. The mouse showing
regression has been followed for over 2 months without
evidence of tumor regrowth. Similar results were obtained in
the C33A tumor model with the subcutaneous injection of
1107 C33A cells in nude mice (data not shown). Two
animals from each treatment group were euthanized 7 days
after the three sequential treatments, and the tumors were
harvested for histological examination. Hematoxylin–eosin
staining revealed that after infection with Ad-E1B19, Ad-
E1B55, Ad-E1B19/55, or Ad-wt, the remaining tumor
mass consisted largely of necrotic tissue.
Minimal toxicity after intratumoral delivery of the
replicating adenoviruses
To evaluate the replicating adenoviruses-related toxicity
after intratumoral injection, histopathological changes in
liver, kidney, and lung were examined for the two mice from
each experimental group that were euthanized 7 days
following three sequential intratumoral adenovirus admin-
istrations. No lesions were found in the liver, kidney, and
lung in all animals examined (data not shown). To further
document the toxicity by the replicating adenovirus treat-
ment, blood samples were collected from animals 5 days
after the last of the three sequential intratumoral treatments.
Serum levels of liver enzymes, GOT, GPT, ALP, T-bili, and
ALB were normal, and no significant differences were found
among groups Table 2. Together, these results indicated that
the intratumoral injection of replicating adenovirus is safe
and well tolerated in mice and thus could be a promising
approach for cancer therapy in humans.
Figure 10 DNA fragmentation analysis. Confluent cultures of U343
cells were treated without ( lane 2) or with CPT at a final concentration
of 1 M ( lane 3). Cells were also treated with E1B mutant ade-
noviruses along with Ad-E1 and Ad-wt as controls ( lanes 4–8).
The cells were harvested at 2 days posttreatment and the formation of
DNA ladder was monitored by electrophoresis on a 2% agarose gel.
DNA smear and the characteristic ladder can be seen in the cells
treated with E1B 19 kDa–attenuated adenoviruses ( lanes 5 and 6) or
CPT ( lane 3), but not in those treated with Ad-E1 ( lane 4), Ad-
E1B55 ( lane 7), or Ad-wt ( lane 8).
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Figure 11 Efficacy of replicating adenoviruses against Hep3B tumors
in female athymic nude mice. Tumors were established by subcuta-
neous implantation of 1107 cells and allowed to grow to an average
size of 60 – 70 mm3. Animals with established tumors were
randomized into five treatment groups of six animals each and
treatment was initiated (day 1). Each group received intratumoral
injection of adenovirus (5108 PFU of adenovirus in 50 L of PBS)
on days 1, 3, and 5 (vertical arrows). Tumor growth was monitored on
a 2- to 3-day interval by measuring the short length and long length
of the tumor. Tumor volume was estimated on the basis of the
following formula: volume=0.523Lw 2.
Table 2 Blood analysis of Hep3B tumor -bearing mice treated with
Ad-E1B19 adenovirus
Description Test Unit Untreated Ad-E1B19
Liver Function GOT U/L 115 84
GPT U/L 29 29
ALP U/L 360 237
T-bili mg/dl 0.4 0.4
ALB g/dl 2.8 2.6
Kidney Function BUN mg/dl 32.5 20.5
CREA mg/dl 1 0.6
Endocrine CA mg/dl 9.6 11.2
Electrolyte Test Na mEq/l 145 134
K mEq/l 7.6 5.5
Cl mEq/l 103 101
GLU mg/dl 161 253
Blood was collected from animals 5 days after the last of the three
sequential intratumoral treatments. Serum levels of liver enzymes,
GOT, GPT, ALP, T-bili, and ALB were normal, and no significant
differences were found among groups.
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Discussion
The importance of E1B 55 kDa gene involved in p53 in-
activation has been studied extensively. Similar activity has
been reported for the E4-ORF6 protein. Like E1B 55 kDa,
E4-ORF6 binds p53 and antagonizes p53-mediated trans-
activation.28,29 The E4-ORF6 and E1B 55 kDa proteins also
regulate the function of p53 by affecting its half - life.30–32
These functions of E1B 55 kDa protein for p53 inactivation
enabled the engineering of E1B 55 kDa–deleted adenovirus
for oncolytic adenovirus specific to p53 mutant cancer cells.
Additionally, the E1B 55 kDa protein performs other
important functions involved in viral replication. Late in
adenovirus infection, large amounts of viral mRNA are
accumulated in the cytosol, whereas cellular mRNA trans-
port and translation are decreased.19 Forming a physical and
functional complex with E4-ORF6, the E1B 55 kDa product
mediates the accumulation of viral mRNA and inhibits the
host cellular mRNA transport and translation.20,33–35 There-
fore, the loss of E1B 55 kDa function endows tumor-
selective replication and cell lysis, but this may compromise
the efficiency of viral replication. To translate this work to a
clinical application, this imperfection of the vector system
could limit the therapeutic effect for cancer treatment.
The requirement of E1B 55 kDa for efficient viral
replication was also demonstrated in our study. In viral
replication assay, only the Ad-E1B19 adenovirus con-
taining the E1B 55 kDa replicated as efficiently as the wild
type among the three E1B -attenuated adenoviruses. The
other two mutant E1B 55 kDa–deleted adenoviruses, Ad-
E1B55 and Ad-E1B19/55, showed reduced viral
replication in comparison to wild- type adenovirus. These
lines of evidence demonstrate that E1B 55 kDa gene is
required in replicating adenoviral gene construct for efficient
viral replication, which is critical for the therapeutic value of
replicating adenovirus for cancer gene therapy.
In a CPE assay, the E1B 19 kDa–inactivated adenovirus
expressing E1B 55 kDa had a greater ability to lyse cells than
the E1B 55 kDa–deleted counterpart Ad-E1B19/55 and
Ad-E1B55 or the wild type. The other E1B 19 kDa–
attenuated mutant adenovirus, Ad-E1B19/55, also
showed more potent cell killing effect (about 5–50 times
higher) than Ad-E1B55. These findings support the
conclusion that the deletion of antiapoptotic protein E1B
19 kDa increased the rate of cell lysis. Sauthoff et al23
previously reported that deletion of the E1B 19 kDa gene
may enhance the cytolytic effects of a replicating adenoviral
vector, which is consistent with our results.
In respect to plaques morphology, the size of plaques
formed by Ad-E1B19 was larger than that of Ad-wt.
Consistent with this, the total number of plaques appeared at
an earlier postinfection period by Ad-E1B19 infection and
was higher than that of Ad-wt. However, Ad-E1B19/55
did not form plaques as fast as Ad-E1B19, even though
both constructs have deletions of the E1B 19 kDa protein.
Formation of plaques is a net result of viral replication in the
cells and the release of virus from infected cells. Thus, a
possible explanation of how the E1B 19 kDa–attenuated
adenovirus, Ad-E1B19, developed larger and more
numbers of plaques than Ad-wt is either that they replicated
more efficiently than wild- type Ad or that the progeny
virions were released faster. From the result of viral
replication assay (Fig 6), it was revealed that Ad-E1B19
replicated at the same rate as that of wild- type adenovirus.
Therefore, its more probable that the deletion of E1B 19 kDa
accelerated the efficient lysis of Ad-infected cells, resulting
in Ad-E1B19 forming the largest plaques that were faster
to develop.
For the elucidation of the underlying mechanism respon-
sible for the rapid cell killing of Ad-E1B19 adenovirus,
several assays detecting apoptosis were employed. The
active induction of apoptosis by Ad-E1B19 and Ad-
E1B19/55 adenoviruses was demonstrated by TUNEL
and DNA fragmentation assay, and efficient cell lysis was
shown by plaque-forming assay. These findings are in
accordance with earlier studies in that infection with the E1B
19 kDa mutant adenovirus caused the induction of cellular
and viral DNA degradation and enhanced CPEs.36–39 In
support of these results, the E1B 19 kDa protein has a well -
established function of interfering with E1A - induced
apoptosis, preventing premature death of the host cells.40,41
In addition, the E1B 19 kDa protein has been shown to
inhibit the cytotoxic action of tumor necrosis factor a
(TNF-a ) or anti -Fas antibodies, both of which induce
apoptosis.42,43 Taken together, these results indicate that the
deletion of the E1B 19 kDa gene in replicating adenovirus
induces E1A -mediated apoptosis as well as direct viral
cytolysis, all of which ultimately lead to increased CPEs,
rapid viral release, improved cell - to-cell spread, active
induction of apoptosis, and efficient viral replication.
In recent clinical trials, tumor-selective replicating
viruses were examined to assess its potential in enhancing
the effect of known chemotherapeutic agents, cisplatin or
5-fluorouracil.7,8 Results showed that the combination of
tumor-selective replicating virus and either of these agents
yielded a significantly better efficacy over treatment with
chemotherapeutic agent alone. TNF-a44 and adenovirus
death protein (ADP)45 have also been shown to enhance the
efficacy of replicating adenoviruses. The E1B 55 kDa gene–
deleted replicating adenovirus, ONYX015, is currently in
phase II clinical trial, being assessed for its ability to enhance
the effect of cisplatin or 5-fluorouracil.2,3 However, to date,
all the replicating adenoviruses used in combination studies
still retain the E1B 19 kDa gene, which, as mentioned before,
is a strong antiapoptotic agent. Because cell death induced by
many chemotherapeutic agents is mainly driven by the
apoptotic pathway, the E1B 19 kDa gene may interfere with
the mode of action of these agents, underestimating the value
of these combination studies.
Our results confirmed previous reports that the deletion of
E1B 19 kDa function enhanced the cytolytic effect.23
Moreover, Ad-E1B19 adenovirus showed potent anti-
tumor effect, suggesting that E1A -mediated apoptosis may
be involved in addition to direct viral - induced cytolysis.
The suppression of apoptosis by E1B 19 kDa was also
demonstrated by earlier reports in which the investigators re-
ported that the E1B 19 kDa protein efficiently prevents cis-
platin- induced apoptosis.46 Taken together, the replicating
adenoviruses deleted in E1B 19 kDa function may serve
as an improved vector for anticancer gene therapy in
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combination with other apoptosis - inducing modalities such
as chemotherapeutic agents and radiation therapy.
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